1 / 7

Hematologic Malignancies Therapeutics Market

Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias.

uday2204
Télécharger la présentation

Hematologic Malignancies Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hematologic Malignancies Therapeutics Market Market Size Worth $87.0 Billion By 2025

  2. Hematologic Malignancies Therapeutics Market Size Worth $87.0 Billion By 2025 “Hematologic Malignancies Therapeutics Market [By Type (Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia), Lymphoma, Multiple Myeloma, and Others); By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others); and By Regions (North America - U.S., Canada; Europe - Germany, UK, France, Italy; Asia-Pacific - China, India, Japan, Australia; Latin America - Brazil, Mexico; Middle East & Africa)]: Market size & Forecast, 2018 – 2025” The Global Hematologic Malignancies Therapeutics Market Size is anticipated to reach over USD 87.0 Billion by 2025 according to a new research published by Polaris Market Research. Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias. Excluding Hodgkin’s lymphoma as well as acute lymphocytic leukemia, these types of malignancy are usually related to growing age. Hence, considering the aging worldwide population, malignancy type is more probable to become more prevalent. The global Hematologic Malignancies Therapeutics Market growth is majorly driven by the increasing focus on development for novel treatments and growing occurrence of blood cancer. Currently, blood malignancies are the second most leading cause of cancer deaths and the 5th most common cancer. The three most common types of blood cancers are multiple myeloma leukemia, and lymphoma. Each year, approximately 400,000 people are diagnosed with lymphoma and more than 300,000 people are diagnosed with leukemia globally. In addition, inventions of novel drugs for blood cancer and its regulatory approvals are anticipated to bolster the market growth. For instance, in 2015, Pfizer announced that its antibody-drug conjugate- inotuzumab has received USFDA approval for acute lymphoblastic leukemia. Browse Detailed Research Report On Hematologic Malignancies Therapeutics Market Analysis: https://www.polarismarketresearch.com/industry-analysis/hematologic- malignancies-therapeutics-market The Global Hematologic Malignancies Therapeutics Market is segmented on the basis of type, therapy, and geography. Based on type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others. The leukemia is further segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. On the basis of type, leukemia was estimated to dominate the market. The major market share is due to availability of - 2 -

  3. Hematologic Malignancies Therapeutics Market Size Worth $87.0 Billion By 2025 products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs. On the basis of therapy, the global Hematologic Malignancies Therapeutics Market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Amongst all the therapies, chemotherapy is the most commonly used treatment with a particular drug or combination of drugs used. On the basis of region, the global Hematologic Malignancies Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was estimated to dominate the global market. The dominance is majorly attributed to the high presence of key market players, availability of branded drugs, established healthcare organization, and increasing government support in the region. However, Asia Pacific is expected to dominate the global market during the forecast period. Increasing awareness about early diagnosis, availability of effective treatment in emerging countries, such as India and China, growing healthcare expenditure, and high unmet clinical needs of patients, are some of the factors anticipated to significantly boost the market in the Asia Pacific. Some major key players in global Hematologic Malignancies Therapeutics Market includes Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company limited among others. The object of the key market players is to deliver better chronic care administration while keeping the cost low. In addition, the companies are concentrating on producing easy-to-use monitoring devices that can aid patients to accomplish conditions including diabetes or heart diseases better by avoiding costly medical processes. - 3 -

  4. Hematologic Malignancies Therapeutics Market Size Worth $87.0 Billion By 2025 Request for sample: https://www.polarismarketresearch.com/industry-analysis/hematologic- malignancies-therapeutics-market/request-for-sample Table of Contents 1. Overview and Scope 1.1. Research goal & scope 1.2. Research assumptions 1.3. Research Methodology 1.3.1. Primary data sources 1.3.2. Secondary data sources 1.4. Key take-aways 1.5. Stakeholders 2. Executive Summary 2.1. Market Definition 2.2. Market Segmentation 3. Hematologic Malignancies Therapeutics Market Insights 3.1. Hematologic Malignancies Therapeutics– Industry snapshot 3.2. Hematologic Malignancies Therapeutics- Ecosystem analysis 3.3. Hematologic Malignancies Therapeutics Market dynamics 3.3.1. Hematologic Malignancies Therapeutics– Market Forces 3.3.1.1. Hematologic Malignancies Therapeutics Market driver analysis 3.3.1.2. Hematologic Malignancies Therapeutics Market restraint/challenges analysis 3.3.1.3. Hematologic Malignancies Therapeutics Market opportunity analysis 3.4. Industry analysis - Porter's five force 3.4.1. Bargaining power of supplier 3.4.2. Bargaining power of buyer 3.4.3. Threat of substitute 3.4.4. Threat of new entrant 3.4.5. Degree of competition 3.5. Hematologic Malignancies Therapeutics Market PEST analysis, 2017 3.6. Hematologic Malignancies Therapeutics Industry trends 3.7. Competitive Ranking Analysis 4. Hematologic Malignancies Therapeutics Market Size and Forecast by Type 4.1. Key findings 4.2. Leukemia 4.2.1. Global market estimates and forecasts, 2017 – 2025 4.2.1.1. Acute Lymphocytic Leukemia 4.2.1.2. Chronic Lymphocytic Leukemia 4.2.1.3. Acute Myeloid Leukemia 4.2.1.4. Chronic Myeloid Leukemia 4.2.2. Lymphoma 4.2.2.1. Global market estimates and forecasts, 2017 – 2025 4.2.3. Multiple Myeloma 4.2.3.1. Global market estimates and forecasts, 2017 – 2025 4.2.4. Others 4.2.4.1. Global market estimates and forecasts, 2017 – 2025 5. Hematologic Malignancies Therapeutics Market Size and Forecast by Therapy 5.1. Key findings 5.2. Chemotherapy - 4 -

  5. Hematologic Malignancies Therapeutics Market Size Worth $87.0 Billion By 2025 5.2.1. Global market estimates and forecasts, 2017 – 2025 5.3. Radiotherapy 5.3.1. Global market estimates and forecasts, 2017 – 2025 5.4. Immunotherapy 5.4.1. Global market estimates and forecasts, 2017 – 2025 5.5. Stem Cell Transplantation 5.5.1. Global market estimates and forecasts, 2017 – 2025 5.6. Others 5.6.1. Global market estimates and forecasts, 2017 – 2025 6. Hematologic Malignancies Therapeutics Market Size and Forecast by Regions 6.1. Key findings 6.2. North America 6.2.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.2.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.2.3. U.S. 6.2.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.2.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.2.4. Canada 6.2.5. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.2.6. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.3. Europe 6.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.3.3. Germany 6.3.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.3.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.3.4. UK 6.3.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.3.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.3.5. France 6.3.5.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.3.5.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.3.6. Italy 6.3.6.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.3.6.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.4. Asia Pacific 6.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.4.3. China 6.4.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.4.3.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.4.4. India 6.4.4.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.4.4.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.4.5. Japan 6.4.5.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.4.5.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.5. Latin America 6.5.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.5.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 6.5.3. Brazil 6.5.3.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 - 5 -

  6. Hematologic Malignancies Therapeutics Market Size Worth $87.0 Billion By 2025 6.5.3.2. 6.5.4. Mexico 6.5.4.1. 6.5.4.2. 6.6. Middle East & Africa 6.6.1. Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 6.6.2. Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 7. Company Profiles 7.1. Pfizer, Inc. 7.1.1. Overview 7.1.2. Financials 7.1.3. Product Benchmarking 7.1.4. Recent Developments 7.2. Hoffmann-LA Roche ltd 7.2.1. Overview 7.2.2. Financials 7.2.3. Product Benchmarking 7.2.4. Recent Developments 7.3. Sanofi-Aventis 7.3.1. Overview 7.3.2. Financials 7.3.3. Product Benchmarking 7.3.4. Recent Developments 7.4. Bristol-Myers Squibb Company 7.4.1. Overview 7.4.2. Financials 7.4.3. Product Benchmarking 7.4.4. Recent Developments 7.5. AbbVie, Inc. 7.5.1. Overview 7.5.2. Financials 7.5.3. Product Benchmarking 7.5.4. Recent Developments 7.6. Novartis AG 7.6.1. Overview 7.6.2. Financials 7.6.3. Product Benchmarking 7.6.4. Recent Developments 7.7. GlaxoSmithKline PLC 7.7.1. Overview 7.7.2. Financials 7.7.3. Product Benchmarking 7.7.4. Recent Developments 7.8. Celgene Corporation 7.8.1. Overview 7.8.2. Financials 7.8.3. Product Benchmarking 7.8.4. Recent Developments 7.9. Johnson & Johnson Services, Inc. 7.9.1. Overview 7.9.2. Financials 7.9.3. Product Benchmarking Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026 Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026 - 6 -

  7. Hematologic Malignancies Therapeutics Market Size Worth $87.0 Billion By 2025 7.9.4. Recent Developments 7.10. Takeda Pharmaceutical Company limited 7.10.1. Overview 7.10.2. Financials 7.10.3. Product Benchmarking 7.10.4. Recent Developments Access Press Release on Hematologic Malignancies Therapeutics Market: https://www.polarismarketresearch.com/press-releases/global-hematologic-malignancies- therapeutics-market About Polaris Market Research Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. E mail Id: sales@polarismarketresearch.com Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com - 7 -

More Related